Buspirone in the Management of Anxiety and Irritability in Children With Pervasive Developmental Disorders: Results of an Open-Label Study
Abstract
BACKGROUND: We evaluated the efficacy and safety of buspirone in the management of anxiety and irritability in children with pervasive developmental disorders (PDD). METHOD: Twenty-two subjects, 6 to 17 years old, with DSM-III-R diagnosed PDD-NOS (N = 20) or autistic disorder (N = 2), were included. They were treated with buspirone in dosages ranging from 15 to 45 mg/day in an open-label trial lasting 6 to 8 weeks. Responders continued buspirone treatment and were followed up for up to 12 months. RESULTS: Nine subjects had a marked therapeutic response and 7 subjects a moderate response on the Clinical Global Impressions (CGI) scale after 6 to 8 weeks of treatment. Side effects were minimal, except for 1 patient who developed abnormal involuntary movements. CONCLUSION: These results suggest that buspirone may be useful for treating symptoms of anxiety and irritability in children with PDD.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In an open-label trial, 22 children and adolescents with ASD (ages 6-17 years) received buspirone (15-45 mg/day) for 6-8 weeks.
“In an open-label trial, 22 children and adolescents with ASD (ages 6–17 years) received buspirone (15–45 mg/day) for 6–8 weeks [105].”
From Pharmacological treatment in autism: a proposal for guidelines on common co-occurring psychiatric symptoms (2025) · cites this paper as [105]
Nine patients (41%) showed a "marked response," and seven participants (32%) showed a "moderate response," addressing target symptoms of anxiety and irritability as measured with the CGI-I.
“Nine patients (41%) showed a “marked response,” and seven participants (32%) showed a “moderate response,” addressing target symptoms of anxiety and irritability as measured with the CGI-I [105].”
From Pharmacological treatment in autism: a proposal for guidelines on common co-occurring psychiatric symptoms (2025) · cites this paper as [105]
The citation lists haven’t been fetched yet
Cited by 113
- Authors
- Buitelaar, J. K., van der Gaag, R. J., & van der Hoeven, J.
- ORCID
- Buitelaar, Jan K.
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 1998-02-15
- Volume
- 59
- Issue
- 2
- Pages
- 56-59
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2024666458
- Cited by
- 113
- References
- 0
- Citations by year
- 2026: 1 · 2025: 4 · 2024: 7 · 2023: 3 · 2022: 3 · 2021: 8 · 2020: 2 · 2019: 3 · 2018: 6 · 2016: 3 · 2015: 6 · 2014: 4 · 2013: 6 · 2012: 10
- FWCI
- 2.13
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cognitive Neuroscience › Autism Spectrum Disorder Research
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
- Keywords
- buspirone, pervasive developmental disorders, autism spectrum disorder, anxiety, irritability, children, atypical antipsychotics, adverse effects
- MeSH terms
- Adolescent, Anxiety, Buspirone, Child, Child Development Disorders, Pervasive, Female, Humans, Irritable Mood, Male, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
